Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

NCT02328014 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkins Lymphoma
Multiple Myeloma
B-All

Interventions

DRUG: Acalabrutinib
DRUG: ACP-319

Sponsor

Acerta Pharma BV

Collaborators

AstraZeneca